Alirocumab Subcutaneous Injection bulk supplier for pharma manufacturers

Alirocumab Subcutaneous Injection 75 mg/mL and 150 mg/mL Suppliers & Bulk Manufacturers

Available Forms: Subcutaneous Injection

Available Strengths: 75 mg/mL and 150 mg/mL

Reference Brands: Praluent(US & EU)

Alirocumab is a monoclonal antibody that inhibits PCSK9, increasing LDL receptor availability to enhance LDL cholesterol clearance from the blood. It effectively lowers LDL levels, reducing cardiovascular risk. Benefits include significant LDL reductions, improved heart health, and prevention of atherosclerotic events in high-risk patients.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description: Alirocumab, marketed as Praluent, is approved in the US by the FDA and in the EU via EMA for lowering LDL cholesterol in patients with familial hypercholesterolemia or cardiovascular risk. Regulatory approval requires a comprehensive dossier including clinical trial data, safety profiles, manufacturing standards, and pharmacovigilance plans. The FDA reviews detailed clinical and quality data to ensure safety and efficacy, while the EMA evaluates regional safety and manufacturing compliance. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Ensuring regulatory adherence supports timely approval, safe use, and global availability of alirocumab subcutaneous injections, contributing to improved cardiovascular health worldwide.

Alirocumab Subcutaneous Injection — third party manufacturing & bulk supply

Alirocumab Subcutaneous Injection 75 mg/mL and 150 mg/mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Alirocumab Subcutaneous Injection is supplied as Subcutaneous Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Alirocumab Subcutaneous Injection listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Alirocumab Subcutaneous Injection →

Back to Listing

Frequently Asked Questions

Alirocumab Subcutaneous Injection is listed as Subcutaneous Injection in 75 mg/mL and 150 mg/mL. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Alirocumab Subcutaneous Injection is referenced against Praluent(US & EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.